RFC
OMED

Russell Frank Company’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Russell Frank Company’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-11,800
Closed -$263K – 2986
2014
Q2 		$263K Sell
11,800
-14,765
-56% -$365K ﹤0.01% 2492
2014
Q1 		$695K Buy
26,565
+7,465
+39% +$252K ﹤0.01% 2245
2013
Q4 		$589K Buy
+19,100
New +$350K ﹤0.01% 2283

Other funds holding OMED

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Russell Frank Company's OMED Position: Q3 2014 in Review

Russell Frank Company sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2014, closing a stake of 11,800 shares — an estimated $263K sold.

Russell Frank Company first reported a position in OMED in Q4 2013 and held it in 3 quarters. The position peaked at $695K in Q1 2014. 62 funds tracked by Wall St. Rank hold OMED as of Q3 2014.

  • Russell Frank Company reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Russell Frank Company sold 11,800 OncoMed Pharmaceuticals, Inc. shares in Q3 2014, an estimated $263K.
  • Russell Frank Company first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 3 quarters.
  • Russell Frank Company's OncoMed Pharmaceuticals, Inc. position peaked at $695K in Q1 2014.
  • 62 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2014.

Based on Russell Frank Company's 13F filing for Q3 2014, filed 12 Nov 2014.